Life Sciences - Microbiology and Microbiome
- Live bacteria and molecules for the treatment of obesity and type 2 diabetes
Symflor is creating a scientifically sound bridge between nutrition and health. Their goal is to cure 21st-century diseases related to gut flora—specifically obesity and type 2 diabetes—through the development of live bacteria and molecules that target these diseases. The company is nurturing the new and complex science of gut microbiota. Symflor aims to bring their products to clinical trials within the next five years.
Symflor was founded by a Cornell faculty member. The company's foundational technology is licensed from Cornell University.